Are HAARTs beneficial for spermatozoa of HIV patients?
Keywords:
HIV/AIDS, HAART, sperm, Assisted reproductive technology, AfricaAbstract
SubSaharan Africa and the major cause of death in the world. The review aims to focus on the effects of highly active antiretroviral therapy (HAART) on the male gametes of HIV positive persons in order to give an insight into the fate of men infected with HIV with respect to their chances of having offsprings following the commencement of HAART.
Methods: This review considered all original and review articles published on Pubmed from year 2000 to 2015. A few selected, exceptionally relevant publications outside this period were also reviewed.
Results: HAART has been shown to improve the health, quality of life and reduction in the morbidity and mortality attributable to HIV-induced immune deficiency. It is anticipated that the survival of patients influence their fertility parameters while on treatment, with focus on young males, within the reproductive age.
Conclusion: A better understanding of the influence of HAART on spermatozoa in patients with HIV/AIDS undergoing therapeutic management is therefore vital for knowledge and a proactive measure in order not to add to their burden if there is expression of the desire to conceive a child.
References
Palella Jr. FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among p a t i e n t s w i t h a d v a n c e d h u m a n
immunodeficiency virus infection. HIV outpatient Study Investigators. N. Engl. J. Med.
; 338, 853–860.
Kayode AAA, Kayode OT, Aroyeun OA, Stephen MC. Hematological and hepatic enzyme alterations associated with acute administration of antiretroviral drugs. J Pharmacol Toxicol.
;6 (3): 293–302.
K u s h n i r VA , L e w i s W. H u m a n i m m u n o d e f i c i e n c y v i r u s / a c q u i r e d immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertil Steril. 2011; 96 (3): 546–550
Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22–29.
Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIVinfected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006; 41:194–200.
Bujan L, Sergerie M, Moinard N, Martinet S, Porte L, Massip P, et al. Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment. J. Androl.
; 28, 444–452.
Hagmann M. Study confirms effectiveness of antiretroviral drugs for HIV patients. Bull World Health Organ. 2003; 81(12):918–919.
Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretrocviral therapy for HIV infection. Can Med Assoc J.
;170:229–238.
Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des.
;11:3697–3710
Soriano V, Puoti M, Garcia-Garsco P, Rockstroh JK, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008; 22: 1–13.
Keiser P, Nassar N, Kvanli MB. Long-term impact of highly active antiretroviral therapy on HIV related health care costs. J Acquir Immune Defic Syndr. 2001;27:14–19.
Suave N, Dzokoto A, Opare B, Kaitoo EE, Khonde N, Mondor M, et al. The price of development: HIV infection in a semiurban community of Ghana. J Acquir Immune Defic Syndr. 2002;29:402–408
CDC. 1981. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep 30: 305–308.
Greene WC. 2007. A history of AIDS: Looking back to see ahead. Eur J Immunol 37 (Suppl. 1): S94–S102
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science.
; 224: 497–500.
Gao F, Bailes E, Robertson DL, Chen Y,
Rodenburg CM, Michael SF, et al. Origin of HIV1 in the chimpanzee Pan troglodytes troglodytes.
Nature. 1999; 397: 436–441.
Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2.
Nature. 1989; 339: 389–392.
Gurtler LG, Hauser PH, Eberle J, von Brunn A, Knapp S, Zekeng L, et al. A new subtype of human immunodeficiency virus type 1 (MVP5180) from Cameroon. J Virol. 1994; 68:
–1585.
Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, et al. Geographical distribution of HIV-1 group O viruses in Africa.
AIDS. 1997; 11: 493–498.
Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller- Trutwin MC, Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O.
Nat Med. 1998; 4: 1032–1037.
Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol, 2011; 85: 1403–1407.
de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: The forgotten AIDS virus. Trends Microbiol.
; 16: 588–595.
Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, et al. Twenty years of prospective molecular epidemiology in Senegal: Changes in HIV diversity. AIDS Res Hum Retroviruses. 2007; 23: 1189–1196.
Rowland-Jones SL, Whittle HC. Out of Africa: What can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol. 2007; 8:
–331.
Damond F, Descamps D, Farfara I, Telles JN, Puyeo S, Campa P, et al. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using realtime PCR. J Clin Microbiol. 2001; 39: 4264–4268.
Ishikawa K, JanssensW, Banor JS, Shinno T, Piedade J, Sata T, et al. Genetic analysis of HIV type 2 from Ghana and Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses. 2001; 17:
–1663.
Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, et al. Human infection by genetically diverse SIVsm-related HIV-2 in west Africa.
Nature. 1992; 358: 495–499.
Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol. 1997; 71: 3953–3960.
Santiago ML, Range F, Keele BF, Li Y, Bailes E,
Bibollet- Ruche F, et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: Implications for the origin of epidemic human immunodeficiency virus type 2. J Virol. 2005; 79: 12515–12527.
Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute-HIV-1 Infection: Basic, clinical and public health perspectives. N Engl J Med. 2011; 364: 1943–1954.
Zambia Central Board of Health. Zambia Demographic and Health Survey 2000–2001. Calverton, MD: Central Board of Health, Zambia and ORC; 2003.
Namibia Ministry of Health and Social Services. Follow-up to the Declaration of Commitment on HIV/AIDS (UNGASS). Namibia Country
Report, 2005. Windhoek, Namibia: Namibia Ministry of Health and Social Services; 2006.
Democratic Republic of Congo: National MultiSectoral Programme for the Response to HIV/AIDS. Report of the Implementation of the Declaration of Commitment of the Heads of State and of Government for the Response to HIV/AIDS in the Democratic Republic of Congo, 2005. Kinshasa, Democratic Republic of Congo; 2006.
Malawi National Statistical Office, ORC Macro. Malawi Demographic and Health Survey. Calverton, MD: National Statistical Office, Zomba, Malawi and ORC Macro; 2004.
Lozano R, Naghavi, Foreman. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
Braveman B, Levin M, Kielhofner G, Finlayson M. HIV/AIDS and return to work: a literature review one-decade post-introduction of combination therapy (HAART). Work J Prev Assess Rehabil. 2006; 27(3):295–303.
Esté, JA and Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Research 85. 2010: 25–33
Detels R, Tarwater P, Phair JP. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15:347–355.
Stenzel MS, Carpenter CC. The management of the clinical complications of antiretroviral therapy. Infect Dis Clin North Am. 2000;14:
–178.
Caron-Debarle M, Boccara M, Lagathu F.
Adipose tissue as a target of hiv-1 antiretroviral drugs. potential consequences on metabolic r e g u l a t i o n s . C u r r P h a r m D e s .
;16:3352–3360.
Vidal F, Gutierrez F, Gutierrez M. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Review.
;12:15–30.
Kartsonis NA, D'Aquila RT. Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing. Infect Dis Clin North Am.
;14:879–899.
Richman DD. HIV chemotherapy. Nature. 2001;410:995–1001
Gulick, Roy MMD, Mellors, JW, Havlir D, Eron, JJ, Gonzalez C, et al. "Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy", The New England journal of medicine 1997;337: 11 734-739.
Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy AIDS 1999, 13:1933–1942
Smyth RP, Davenport MP, Mak JM. The origin of genetic diversity in HIV-1. Virus Research. 2012; 169: Pages 415–429
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 Aug;120(8):713-9.
Piomboni, P, Baccetti, B. Spermatozoon as a vehicle for HIV-1 and other viruses: a review. Molecular Reproduction and Development. 2000 56: 238–242.
Gadella B M, Hammache D, Pieroni G,
Colenbrander B, van Golde LM Fantini J. Glycolipids as potential binding sites for HIV: topology in the sperm plasma membrane in relation to the regulation of membrane fusion. Journal of Reproductive Immunology. 1998; 41:
–253.
Muciaccia B, Padula F, Gandini L, Lenzi A, Stefanini M. HIV-1 chemokine co-receptor CCR5 is expressed on the surface of human spermatozoa. AIDS. 2005; 19, 1424–1426.
Fanibunda SE, Velhal SM, Raghavan VP, Bandivdekar AH. CD4 independent binding of HIV gp120 to mannose receptor on human spermatozoa. J Acquir Immune Defic Syndr. 2008; 48(4): 389-97
Baccetti B, Benedetto A, Burrini AG, Collodel G, Ceccarini EC, Crisa N. HIV-particles in spermatozoa of patientswith AIDS and their transfer into the oocyte. The Journal of Cell Biology. 1994; 127, 903–914.
Dulioust E, Du AL, Costagliola D, Guibert J, Kunstmann JM, Heard I, et al. Semen alterations in HIV-1 infected men. Hum Reprod. 1998; 17:2112–2118
Tachet A, Dulioust E, Salmon D, De Almeida M, Rivalland S, et al. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS. 1999; 13, 823–831.
Hanabusa H, Kuji N, Kato S, Tagami H, Kaneko S, Tanaka H, et al. An evaluation of semen processing methods for eliminating HIV-1. AIDS.
; 14: 1611–1616.
Leruez-Ville M, de Almeida M, Tachet A, Dulioust E, Guibert J, Mandelbrot L, et al. Assisted reproduction in HIV-1-serodifferent couples: the need for viral validation of processed semen. AIDS. 2002 Nov 22;16 (17):2267-73.
Muciaccia B, Corallini S, Vicini E, Padula F, Gandini L, Liuzzi G, et al. HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Human Reproduction.
; 22, 2868–2878.
Le Tortorec A, Dejucq-Rainsford N. HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl. 2010; 33(1):e98-108
van Leeuwen E, Wit F, Prins J, Reiss P, van der Veen F, Repping S. Semen quality remains stable during 96 weeks of untreated human immunodeficiency virus-1 infection. Fertil Steril.
; 90: 636–641
Wang D, Li L, Xie Q, Hou Z, Yu X, Ma M, et al. Factors affecting sperm fertilizing capacity in men infected with HIV. J Med Virol. 2014; 86(9):1467-72
Crittenden JA, Handelsman DJ, Stewart GJ. Semen analysis in human immunodeficiency virus infection. Fertil Steril. 1992; 57:1294–1299
Dondero F, Rossi T, D'OYzi G, Mazzilli F, Rosso R, Sarandrea N, et al. Semen analysis in HIV seropositive men and in subjects at high risk for HIV infection. Hum Reprod. 1996; 11:765–768.
Krieger JN, Coombs RW, Collier AC, Koehler JK, Ross SO, Chaloupka K, et al. Fertility parameters in men infected with human immunodeficiency virus. J Infect Dis. 1991; 164:464–469
Nicopoullos JD, Almeida PA, Ramsay JW, Gilling-Smith C. The effect of human immunodeWciency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod. 2004; 19:2289–2297
Kehl S, Weigel M, Müller D, Gentili M, Hornemann A, Sütterlin M. HIV-infection and modern antiretroviral therapy impair sperm quality. Arch Gynecol Obstet. 2011;284 (1):229-
Cardona-Maya W, Velilla P, Montoya CJ, Cadavid A, Rugeles MT. Presence of HIV-1 DNA in spermatozoa from HIV positive patients: changes in the semen parameters. Curr HIV Res.
; 7: 418–424.
Pavili L, Daudin M, Moinard N, Walschaerts M, Cuzin L, Massip P, et al. Decrease of mitochondrial DNA level in sperm from patients infected with human immunodeficiency virus-1 linked to nucleoside analogue reverse transcriptase inhibitors. Fertil Steril. 2010; 94:2151–2156
Diehl S, Vernazza P, Trein A, Schnaitmann E,
Grimbacher B, Setzer B, Walker UA.
Mitochondrial DNA and sperm quality in patients under antiretroviral therapy. AIDS. 2003; 17:450–451
Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995; 1(5):417–422.
Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12(14):1735–1744
Robbins WA, Witt KL, Haseman JK, Dunson DB, Troiani L, Cohen MS. Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. J Infect Dis 2001; 184:127–135.
Lambert-Niclot S, Poirot C, Tubiana R, Houssaini A, Soulié C, Dominguez S, et al. Effect of antiretroviral drugs on the quality of semen. J Med Virol. 2011; 83(8):139 1-4.
Sharma B. Anti-HIV-1 drug toxicity and management strategies. Neurobehav HIV Med. 2011;3:27–40.
Azu OO. Highly active antiretroviral therapy (HAART) and testicular morphology: current status and a case for a stereologic approach. J Androl. 2012;33(6):1130–1142.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Research Journal of Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Research Journal of Health Sciences journal is a peer reviewed, Open Access journal. The Journal subscribed to terms and conditions of Open Access publication. Articles are distributed under the terms of Creative Commons License (CC BY-NC-ND 4.0). (http://creativecommons.org/licences/by-nc-nd/4.0). All articles are made freely accessible for everyone to read, download, copy and distribute as long as appropriate credit is given and the new creations are licensed under the identical terms.
